Impact of the MonCœur smartphone application on self-care and quality of life in heart failure: The APPLIMONCOEUR randomized trial - 02/06/26
, Etienne Audureau c, Claire Bouleti d, Antoine Jobbe Duval e, Marjorie Canu f, Romain Itier g, Lise Legrand h, Mazen Alloujami i, Jean-Michel Tartiere j, Philippe Degroote k, Damien Logeart l, François Roubille m, Anne-Céline Martin n, Thibaud Damy c, Fabrice Bauer a, bGraphical abstract |
Highlights |
• | We evaluated the impact of the MonCœur app versus usual care in patients with HF. |
• | At 6 months, no significant differences were observed in self-care or quality of life. |
• | Exploratory analyses at 12 months showed increased physical activity among app users. |
• | Medication adherence tended to improve in the app group, suggesting a potential benefit. |
• | Patient engagement with the app was moderate, highlighting a need for integration into usual care. |
Abstract |
Background |
The MonCœur smartphone application (app) was developed to meet the specific needs of individuals living with heart failure (HF).
Aims |
To evaluate whether the MonCœur smartphone app improves self-care at 6 months in patients with HF, and to assess effects on quality of life, physical activity and medication adherence.
Methods |
APPLIMONCOEUR was a prospective, multicentre, randomized, controlled, open-label trial conducted in 12 HF centres in France. Adults with HF (left ventricular ejection fraction ≤ 40%) hospitalized for de novo or decompensated HF, or within 3 months of discharge, were randomized 1:1 to usual care or usual care plus MonCœur mobile app. Follow-up occurred at baseline, 3, 6 (primary timepoint) and 12 months. The primary endpoint was change in self-care (European Heart Failure Self-care Behaviour Scale [EHFSCB] score) at 6 months. Secondary endpoints included health-related quality of life (Minnesota Living with Heart Failure Questionnaire [MLWHFQ] score), weekly physical activity (mins/week per World Health Organization categories) and medication adherence (Girerd questionnaire). Analyses were performed on the intention-to-treat population with multiple imputation; between-group differences at follow-up were assessed using analysis of covariance adjusted for baseline values.
Results |
Among 123 randomized patients (control n = 64; app n = 59), baseline characteristics and therapies were well balanced. At 6 months, no significant difference was found for self-care (EHFScB total P = 0.23). Quality of life improved similarly in both groups (MLWHFQ total P = 0.87). Physical activity increased in both groups, with no between-group differences at 6 months (intensive P = 0.92; moderate-to-intensive P = 0.63), but exploratory 12-month analyses favoured the app ( P = 0.002 and P = 0.008, respectively). Medication adherence increased modestly in both groups ( P = 0.12). Only 25/59 (42.4%) of app users were active (i.e. used the app at least 3 times during the study).
Conclusion |
The MonCœur randomized trial suggests that a mobile app dedicated to HF management may contribute to behavioural changes, particularly in physical activity, although patient engagement with the app was moderate.
ClinicalTrials.gov |
NCT04198779 .
Le texte complet de cet article est disponible en PDF.Keywords : Heart failure, MHealth, Self-care, Digital health
Plan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?